NeuroBo Pharmaceuticals, Inc. (NRBO)
NASDAQ: NRBO · Real-Time Price · USD
2.880
-0.020 (-0.69%)
Oct 22, 2024, 4:00 PM EDT - Market closed
NeuroBo Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Selling, General & Admin | 7.39 | 6.73 | 8.64 | 8.75 | 7.85 | 2.7 | |
Research & Development | 19.14 | 9.16 | 2.78 | 6.55 | 4.53 | 5.32 | |
Operating Expenses | 26.53 | 15.89 | 11.42 | 15.3 | 12.38 | 8.03 | |
Operating Income | -26.53 | -15.89 | -11.42 | -15.3 | -12.38 | -8.03 | |
Interest Expense | - | - | -2.19 | - | - | -0.13 | |
Interest & Investment Income | 0.86 | 0.46 | - | 0.01 | 0.04 | 0.11 | |
Currency Exchange Gain (Loss) | - | - | -0.01 | - | -0 | - | |
Other Non Operating Income (Expenses) | -0.24 | 2.96 | 7.94 | - | - | - | |
EBT Excluding Unusual Items | -25.9 | -12.47 | -5.68 | -15.28 | -12.34 | -8.05 | |
Gain (Loss) on Sale of Assets | - | - | -0.08 | - | - | - | |
Other Unusual Items | - | - | - | - | - | -1.11 | |
Pretax Income | -25.9 | -12.47 | -13.97 | -15.28 | -29.68 | -21.31 | |
Net Income | -25.9 | -12.47 | -13.97 | -15.28 | -29.68 | -21.31 | |
Net Income to Common | -25.9 | -12.47 | -13.97 | -15.28 | -29.68 | -21.31 | |
Shares Outstanding (Basic) | 5 | 5 | 0 | 0 | 0 | 0 | |
Shares Outstanding (Diluted) | 5 | 5 | 0 | 0 | 0 | 0 | |
Shares Change (YoY) | 84.99% | 1476.33% | 233.62% | 42.70% | 210.43% | 22.88% | |
EPS (Basic) | -5.01 | -2.46 | -43.42 | -158.50 | -439.21 | -979.10 | |
EPS (Diluted) | -5.01 | -2.46 | -43.42 | -158.50 | -439.21 | -979.10 | |
Free Cash Flow | -19.95 | -10.85 | -11.71 | -15.14 | -10.77 | -7.25 | |
Free Cash Flow Per Share | -3.86 | -2.14 | -36.41 | -156.98 | -159.36 | -333.21 | |
EBITDA | -26.51 | -15.88 | -11.4 | -15.25 | -12.33 | -8.01 | |
D&A For EBITDA | 0.02 | 0.01 | 0.02 | 0.05 | 0.05 | 0.02 | |
EBIT | -26.53 | -15.89 | -11.42 | -15.3 | -12.38 | -8.03 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.